Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760549 · ClinicalTrials.gov registry record
Study of the Safety and Immunogenicity of NasoVAX Extension
A clinical trial, sponsored by Altimmune.
- Completed
- Registry status
- 8
- Enrollment target
NCT03760549 is a clinical trial that has completed, run by Altimmune. The registered enrollment target is 8 participants.
The verdict
NCT03760549 has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
This study is an extension to Study ALT-103-201, a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age.
Interventions
- DRUG Subjects were administered NasoVAX high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-01-21 |
| Est. Completion | 2019-02-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03760549
The ClinicalTrials.gov registry entry for NCT03760549 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Subjects were administered NasoVAX high dose is the first listed.
NCT03760549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03760549 about?
NCT03760549 is a clinical study titled "Study of the Safety and Immunogenicity of NasoVAX Extension". This study is an extension to Study ALT-103-201, a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age.
What is the current status of trial NCT03760549?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2019-01-21. Estimated completion is 2019-02-18.
What interventions are being tested in trial NCT03760549?
The interventions under investigation include: Subjects were administered NasoVAX high dose (DRUG).
Who is sponsoring clinical trial NCT03760549?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.